Abstract
Cytotoxic drugs were designed to kill tumor cells, whereas agents of molecular targeted therapy inhibit various molecular functions of the tumor cell. Consequently, their toxicity profiles also differ. Molecular targeted agents, except for monoclonal antibodies, are enumerated here in three classes: compounds active extracellularly, extra/intracellularly, and intracellularly. Although no major breakthrough has occurred in the drug treatment of neoplastic diseases yet, such compounds as trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, imatinib, and bortezomib have shown considerable clinical promise. Major obstacles to the further development of molecular targeted compounds are described. The use of different endpoints, positron emission tomography for evaluation, and predictive genetic markers are recommended. Combination therapy with cytotoxic drugs and studies in an adjuvant setting are also recommended. It is concluded that cautious optimism about the future of molecular targeted therapy is reasonable.
References
Jan 3, 1990·Journal of the National Cancer Institute·J Folkman
Jun 1, 1997·Nature Medicine·C HeiseD H Kirn
Mar 15, 2001·The New England Journal of Medicine·D J SlamonL Norton
Jul 18, 2001·Pathology Oncology Research : POR·J TímárS Paku
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A QuinnHenry S Friedman
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoinette R TanAdrian M Senderowicz
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen R D JohnstonAngela Howes
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian J Druker
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Feb 26, 2004·Seminars in Oncology·Edward S KimMerrill S Kies
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael B AtkinsMatthew L Sherman
Apr 13, 2004·Current Opinion in Oncology·Greg R AngstreichRichard J Jones
Apr 13, 2004·Current Opinion in Oncology·Cesare Gridelli
May 1, 2004·The New England Journal of Medicine·Thomas J LynchDaniel A Haber
Jul 3, 2004·The Lancet Oncology·Benedetto BrunoMario Boccadoro
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Oct 27, 2004·Cancer Science·Nagahiro Saijo
Nov 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harri SihtoHeikki Joensuu
Nov 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neelam T ShahVincent A Miller
Jun 22, 1946·Journal of the American Medical Association·C P RHOADS
Citations
Jan 1, 2008·PET Clinics·Rodney J Hicks
Sep 18, 2008·International Journal of Cancer. Journal International Du Cancer·Dimitri MoreauChristos Roussakis
Aug 3, 2010·The British Journal of Nutrition·Srimathi Kannan
Jan 22, 2009·Avian Pathology : Journal of the W.V.P.A·Ulrike FoldenauerJean-Michel Hatt
Mar 26, 2014·Journal of Animal Physiology and Animal Nutrition·F WyssA Liesegang
Jan 5, 2020·Anatomia, histologia, embryologia·Gisele J Dos SantosAlessandra Melchert